FIGURES
Figure 1. Study timeline and profile of the study participants.
CVID, common variable immunodeficiency; HCs, healthy controls; AE,
adverse events; SAE, severe adverse events; RT-PCR, reverse
transcription polymerase chain reaction; pts., patients
Figure 2. Humoral immune response in patients with CVID and
HCs. A : Serum concentrations of anti-RBD SARS-CoV-2 specific
antibodies at months 1 (M1), 3 (M3), and 6 (M6) measured by the
immunoblot (IB; positive cutoff value >180 U/mL marked as
grid line, graph A) or B : enzyme-linked immunosorbent (ELISA;
positive cutoff value >18 U/mL marked as grid line) assays.C : Virus-neutralizing antibody titer (Ab) at month 1 (positive
cut-off value >1:20); * p < 0.05, **p < 0.01, *** p < 0.001, **** p< 0.000. NS, not significant; CVID, common variable
immunodeficiency; HC, healthy controls; RBD, receptor-binding domain
Figure 3. T-cell immune response. The proportion of
IFNγ/TNFα/IL-2 producing CD4+ T cells (total count) in patients with
CVID and HC measured at months 1 and 6. CVID, common variable
immunodeficiency; HC, healthy controls; IFN, interferon; TNF, tumor
necrosis factor; IL, interleukin
Figure 4. Summary of adverse events (AEs) observed in the
study’s participants. The incidence of AEs (as % of 21 enrolled
patients) after the first and the second dose. No severe adverse events
(SAEs) were reported.
Supplementary Figure 1. Gating of SARS-CoV-2 S-RBD-specific
response of T cells. CD4+ or CD8+ T cells were gated from lymphocyte,
and CD3+ T cells were gated after the removal of CD14 monocytes, CD20 B
cells, and doublets. All combinations of cytokine production upon
antigen stimulation (interferon-γ, interleukin-2, and tumor necrosis-α)
were gated and reported.